Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
58
resultados
Última actualización
01/09/2024 [06:45:00]
Resumen de: US2024285773A1
Methods of monitoring therapeutic efficacy in a subject with myelodysplastic syndrome (MDS) are provided. Also provided is a method of identifying a subject with MDS for treatment with a telomerase inhibitor, and methods of treating MDS. The methods include administering to the subject a telomerase inhibitor and assessing variant allele frequency (VAF) for one or more of the following genes: SF3B1, TET2, DNMT3A, ASXL1, and CUX1 in a biological sample obtained from the subject after administration of the telomerase inhibitor. In some cases, a 25% or more reduction in VAF identifies a subject who has an increased likelihood of benefiting from treatment with a telomerase inhibitor. In some instances, the telomerase inhibitor is imetelstat or imetelstat sodium.
Resumen de: WO2024175887A1
The invention relates to methods of using saRNAs targeting C/EBPα and pharmaceutical compositions comprising the saRNAs to treat diseases such as cancer including acute myeloid leukemia (AML).
Resumen de: WO2024175803A1
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of myeloid disorders, such as acute myeloid leukemia (AML), in subjects having at least one chromosome abnormality of 3q21 and/or 3q26.
Resumen de: WO2024178305A1
The present disclosure provides mRNAs encoding an IL- 15 fusion protein comprising an IL- 15 polypeptide, an IL-15Rα polypeptide, and half-life extending moiety and methods of treating cancer, including solid tumors and disseminated cancers such as myeloid malignancies (e.g., multiple myeloma), using the mRNAs described herein, optionally formulated as lipid nanoparticles.
Resumen de: US2024285624A1
The present disclosure relates generally to the use of an ERK1/2 inhibitor or a SHP2 inhibitor in combination with a FLT3 inhibitor, such as gilteritinib, for treating cancer, specifically acute myeloid leukemia (AML).
Resumen de: AU2023224879A1
The present invention is directed to compounds of Formula (I), characterized as PROTACs of MALT1. The PROTACs described herein can be useful in the treatment of diseases or disorders associated with MALT1, such as lymphoma. In particular, the invention is concerned with compounds and pharmaceutical compositions capable of degrading MALT1, methods of treating diseases or disorders associated with MALT1, and methods of synthesizing these compounds. (I)
Resumen de: WO2024178339A2
Provided herein are methods for treating neuroblastoma characterized as having genetic aberrations in ALK, FAK, and/or MYCN with ESK440.
Resumen de: US2024287182A1
This invention relates to methods and compositions for use in treating cancer in a subject. For example, the invention relates to methods and compositions for use in treating esophageal cancer or colorectal cancer (CRC) (e.g., metastatic CRC (e.g., microsatellite instability (MSI) high (MSI-H) metastatic CRC)) in a subject by administering to the subject an anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) antagonist antibody (e.g., tiragolumab) and a PD-1 axis binding antagonist (e.g., atezolizumab); methods and compositions for use in treating metastatic CRC (e.g., MSI-H metastatic CRC) in a subject by administering to the subject an anti-TIGIT antagonist antibody (e.g., tiragolumab), a PD-1 axis binding antagonist (e.g., atezolizumab), and an anti-VEGF antibody (e.g., bevacizumab); methods and compositions for use in treating melanoma in a subject by administering to the subject a bispecific antibody targeting programmed cell death protein 1 (PD-1) and lymphocyte activation gene-3 (LAG3), optionally with an anti-TIGIT antagonist antibody (e.g., tiragolumab); and methods and compositions for use in treating a CD20-positive cell proliferative disorder (e.g., non-Hodgkin's lymphoma (NHL); e.g., relapsed or refractory NHL) in a subject by administering to the subject a bispecific antibody targeting CD20 and CD3 (mosunetuzumab) and an anti-TIGIT antagonist antibody (e.g., tiragolumab), optionally with a PD-1 axis binding antagonist (e.g., atezolizumab).
Resumen de: US2024285592A1
Human therapeutic treatment compositions comprising a curcumin component, a harmine component, and an isovanillin component, preferably all three in combination. The agents are synergistically effective for treatment of human conditions, especially human cancers, such as brain or central nervous system lymphomas or tumors.
Resumen de: US2024287062A1
The present disclosure relates to compounds and compositions for inhibition of RAF serine/threonine protein kinases and inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as melanoma, non-small cell lung cancer, and chronic myeloid leukemia (CML).
Resumen de: EP4420683A1
It is an object to provide an antibody specifically binding to CD37-positive tumor cells such as malignant B-cell lymphoma, an antibody-drug conjugate comprising the antibody, a pharmaceutical composition having therapeutic effects on a tumor using the antibody, a method for treating a tumor using the aforementioned pharmaceutical composition, a method for producing the antibody, and a method for producing the antibody-drug conjugate, and the like. The present invention provides an anti-CD37 antibody-drug conjugate in which an antibody is conjugated to a drug linker represented by the following formula (wherein A represents a connecting position to the antibody) by a thioether bond, specifically, a humanized anti-CD37 antibody having internalization ability and an antibody-drug conjugate containing the antibody.
Resumen de: TW202329969A
This invention relates to pharmaceutical compositions, pharmaceutical combinations and methods for the treatment of acute myeloid leukemia by combined use of a therapeutically effective combination of a compound of Chemical Formula 1, or a pharmaceutically acceptable salt thereof, solvate thereof, stereoisomer thereof, tautomer thereof, or combination thereof, wherein Ea, Eb, Ec, Ed, Z', X', Q, and k are defined herein; and a Bcl-2 inhibitor, or a Bcl-2 inhibitor and a hypomethylating agent.
Resumen de: WO2024170646A1
The present invention relates to novel antagonists of the Liver X Receptors (LXRs) of formula (I) and (II) which can be used alone or in combination with other anti cancer therapies, such as the immune checkpoint blockers or cell adoptive cell therapy, preferably T cell adoptive cell therapy, to treat different cancers, including melanoma, Hodgkin lymphoma, renal, lung, bladder and head and neck cancers.
Resumen de: WO2024170627A1
The present invention provides therapeutics for the treatment of CCR9-positive cancers such as T-cell acute lymphoblastic leukemia. In particular, the present invention provides a CCR9 targeting moiety. The present invention furthermore relates to a CCR9 targeting moiety comprising a further targeting moiety, preferably a CD1a targeting moiety, a dual CAR comprising a CCR9 and a CD1a targeting moiety, their use in the treatment of CCR9 and/or CD1a positive cancers, and the use of a CCR9 targeting moiety and a separate CD1a targeting moiety for such treatment.
Resumen de: US2024279201A1
Compounds and compositions are provided as inhibitors of the Wnt/beta-catenin pathway and/or activators of the adenosine monophosphate-activated kinase (AMPK) pathway for the treatment of diseases that implicate the same. Such diseases include cancer or a metabolic disease. Cancers that may be treated by these compounds and compositions include adrenocortical cancer, hepatocellular cancer, hepatoblastoma, malignant melanoma, ovarian cancer, Wilm's tumor, Barrett's esophageal cancer, prostate cancer, colon cancer, colorectal cancer, rectal cancer, pancreatic cancer, bladder cancer, breast cancer (e.g. triple negative breast cancer), gastric cancer, head & neck cancer, lung cancer, mesothelioma, cervical cancer, uterine cancer, myeloid leukemia cancer, lymphoid leukemia cancer, pilometricoma cancer, medulloblastoma cancer, glioblastoma, and familial adenomatous polyposis. Metabolic diseases include type 2 diabetes, obesity, hyperlipidemia, alcoholic or non-alcoholic fatty liver disease, and liver fibrosis.
Resumen de: US2024279337A1
Disclosed herein is anti-human CD276 mAb expressing the Fc-fused fragments from the extracellular domain of human CD276 (Leu29-Pro245), producing the N-glycosylated peptides as immunogen, and generating hybridoma cells through fusing mouse splenocytes and myeloma cells. The specific targeting of cancer cells and intracellular release of potent drugs enables high anti-cancer efficiency and minimal side effects.
Resumen de: US2024280560A1
The present invention relates to diagnostic screens, antibodies, methods and kits for detection/prognosis of acute myeloid leukaemia. The diagnostic screen detects the presence (+) or absence (−) of the cell surface polypeptide markers i) CD34+; ii) CD45RA+; and iii) CD90− and/or CD123+. Antibodies specific for one or more of said cell surface polypeptide markers may be used in the diagnostic screen of the invention. Diagnostic and prognostic methods for detecting and monitoring minimal residual disease based on said screen also form part of the invention.
Resumen de: US2024279307A1
The present disclosure provides compositions and methods for targeting a minor histocompatibility (H) antigen (HA-1H) to, for example, prevent or manage relapse of a hematological malignancy after allogeneic hematopoietic stem cell transplantation (HCT). Also provided are transgene constructs encoding engineered binding proteins, such as a T cell receptor or a chimeric antigen receptor, optionally encoding additional components such as a co-receptor and/or safety switch. Such transgene constructs can be transduced into an immune cell, such as a T cell, and used as an immunotherapy in a subject having a hematological malignancy or at risk for recurrence of the hematological malignancy (e.g., leukemia, lymphoma, myeloma).
Resumen de: US2024279740A1
Novel methods for diagnosing and treating diffuse large B-cell lymphoma (DLBCL) and/or primary central nervous system diffuse large B-cell lymphoma (PCNSL) are provided herein. The present invention provides a set of methylation markers which were identified in silico and confirmed in archival and tissue samples could achieve 100% accuracy to discriminate DLBCL and/or PCNSL from other CNS neoplasms. The markers can be identified using QM-MSP and a novel simpler, faster, qMSP assay called TAM-MSP.
Resumen de: US2024277631A1
A method of inhibiting the development of osteoclasts in patients having multiple myeloma comprising administering to a patient having multiple myeloma a therapeutically effective amount of N-Methyl-dichloropropionaniline (i.e. also known as ELP-004) for inhibiting the development of osteoclasts. The method includes wherein said N-Methyl-dichloropropionaniline is administered to said patient in a pharmaceutically acceptable vehicle.
Resumen de: US2024277749A1
There is provided a pharmaceutical formulation that is useful in the treatment of myelodysplastic syndrome, comprising a plurality of particles suspended in an aqueous carrier system, which particles: (a) have a weight-, number-, or volume-based mean diameter that is between amount 10 nm and about 700 μm; and (b) comprise solid cores comprising azacitidine, or a pharmaceutically-acceptable salt thereof, coated, at least in part, by a coating of inorganic material comprising mixture of: (i) zinc oxide; and (ii) one or more other metal and/or metalloid oxides, wherein the atomic ratio ((i):(ii)) is between at least 1:6 and up to and including about 6:1. Said mixed oxide coated particles are preferably synthesized via a gas phase coating technique, such as atomic layer deposition. The formulation may provide for the delayed or sustained release of azacitidine to treat myelodysplastic syndrome without a burst effect.
Resumen de: US2024277765A1
Provided herein are acute myeloid leukemia antigen targets for chimeric receptors and methods of using same.
Resumen de: US2024277856A1
Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.
Resumen de: AU2023213840A1
Neuroblastoma (NB) remains a leading cause of childhood cancer morbidity and mortality. Heritable activating mutations are present in the anaplastic lymphoma kinase (ALK) oncogene and these same mutations are frequently somatically acquired during high-risk NB tumorigenesis. ALK has been established as a tractable molecular target in NB and provides the rationale for the clinical development of ALK inhibition therapy. Anti-ALK antibodies and antigen binding fragments thereof are provided along with methods of use thereof.
Nº publicación: AU2023219348A1 22/08/2024
Solicitante:
HADASIT MEDICAL RES SERVICES AND DEVELOPMENT LTD
BAR ILAN UNIV
HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD,
BAR ILAN UNIVERSITY
Resumen de: AU2023219348A1
The present disclosure provides chimeric antigen receptor (CAR) molecule specific for B cell maturation antigen (BCMA), compositions and methods for treating immune-related disorders, specifically, plasma cell pathologies such as multiple myeloma (MM).
BOPI
Sede Electrónica
